Regeneron Pharmaceuticals, Inc. (LON:0R2M)
648.75
-3.50 (-0.54%)
At close: Nov 7, 2025
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.75B USD in the quarter ending September 30, 2025, with 0.90% growth. This brings the company's revenue in the last twelve months to $14.25B, up 2.89% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.25B
Revenue Growth
+2.89%
P/S Ratio
4.83
Revenue / Employee
$943.19K
Employees
15,106
Market Cap
51.24B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Regeneron Pharmaceuticals News
- 18 hours ago - Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% - Investor's Business Daily
- 21 hours ago - Regeneron Reports Promising Phase 2 Results For Novel Factor XI Antibodies In Knee Surgery Patients - Nasdaq
- 1 day ago - UBS Raises Regeneron Pharmaceuticals (REGN) Price Target to $660 | REGN Stock News - GuruFocus
- 1 day ago - REGN: Regeneron and Sanofi Report Positive Dupixent Trial Results - GuruFocus
- 1 day ago - Regeneron and Sanofi's Dupixent succeeds in late-stage study - Seeking Alpha
- 2 days ago - Sanofi And Regeneron's Dupixent Meets Primary Goal In Phase 3 Allergic Fungal Rhinosinusitis Study - Nasdaq
- 2 days ago - Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review - Benzinga
- 2 days ago - Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review - GlobeNewsWire